^
Association details:
| Biomarker: | PD-L1 negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Excerpt:
...The exception to this is patients with NSCLC who test negative for PD-L1 expression or are unevaluable for PD-L1 expression must have received prior platinum-based chemotherapy for entry into Cohort 2....
Trial ID:
Source:
Title:
Pembrolizumab plus chemotherapy for advanced non–small-cell lung cancer without tumor PD-L1 expression in Asia
Published date:
07/19/2023
Excerpt:
For pembrolizumab plus chemotherapy versus chemotherapy alone, median overall survival was 21.3 versus 12.6 months (HR, 0.55 [95% CI: 0.35-0.87]) and median progression-free survival (PFS) was 8.4 versus 6.0 months (HR, 0.64 [95% CI: 0.43-0.96])….The analysis supports the use of pembrolizumab in combination with platinum-based chemotherapy for East Asian patients with PD-L1-negative, advanced NSCLC.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.2217/imt-2023-0043
Source:
Title:
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials
Published date:
09/11/2020
Excerpt:
Among patients with PD‐L1‒negative tumors, the ORR was higher with pembrolizumab plus chemotherapy (50.0%; 95% CI, 43.7%‐56.3%) than chemotherapy alone (29.8%; 95% CI, 23.4%‐36.9%).
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1002/cncr.33142
